Weight loss drugs like Ozempic have been sold as a way to help people shed pounds and reclaim their health. A new study complicates that promise, finding that many people on semaglutide moved less after losing weight instead of becoming more active. The research suggests that medication alone may not deliver the metabolic reset patients and clinicians expect.
As Ozempic and related GLP-1 drugs surge in popularity, the findings raise hard questions about how these injections interact with muscle, energy, motivation and long-term weight maintenance. They also underscore a growing divide between the biology of weight loss and the social stories being told about it.
What researchers actually saw when Ozempic users lost weight
The new study tracked adults with overweight or obesity who were prescribed semaglutide and followed their progress over time. Participants lost a significant amount of weight, but objective activity monitors showed that their daily movement declined even as the number on the scale dropped. The expectation that lighter bodies would automatically translate into more steps and more exercise did not hold up when researchers looked at the data.
Scientists had predicted that reduced joint pain, easier breathing and better blood sugar control would nudge people toward more movement. Instead, the team reported that average daily physical activity fell, and sedentary time increased, once participants were established on the drug. The counterintuitive pattern was detailed in the original research summary shared through ScienceDaily, which emphasized that the medication’s impact on behavior did not match early hopes.
Separate work has already raised red flags about how GLP-1 medications affect body composition. A group at University of Utah Health found that patients using semaglutide lost not only fat but also meaningful amounts of lean mass and strength, prompting concern that the drug might accelerate or mimic age-related muscle loss. That team’s report from Utah Health suggested that without a focus on resistance training and protein intake, some users could emerge lighter but physically weaker.
Layered on top of those muscle findings, the new movement data reveal a pattern. People on Ozempic may be losing weight in a way that does not always support stronger, more capable bodies. Less physical activity, combined with lean mass loss, could blunt improvements in cardiovascular fitness and mobility that typically accompany lifestyle-based weight loss.
Why less movement on Ozempic matters for health and expectations
For clinicians, the study challenges a common assumption that weight loss, however achieved, automatically improves physical functioning. Researchers who expected semaglutide to act as a springboard into more exercise instead documented a drop in activity, a result highlighted in coverage from SciTechDaily. That disconnect has real implications for how these drugs are prescribed and monitored.
Physical activity is one of the strongest predictors of long-term health, independent of weight. Regular movement improves insulin sensitivity, blood pressure, mood and sleep, and it helps preserve muscle and bone. If patients lose weight but become more sedentary, they may not see the full cardiometabolic benefits that clinical trials associate with GLP-1 medications. Over time, lower activity could also make weight regain more likely once the drug is reduced or stopped.
Metabolically, the body often responds to weight loss with a drop in resting energy expenditure and a stronger drive to conserve energy. That can show up as subtle fatigue, less spontaneous movement and a tendency to sit more. The new data suggest that Ozempic does not fully override those built-in defenses. Instead, the medication seems to change appetite and food intake while leaving, or even amplifying, the body’s inclination to move less after weight loss.
The findings also collide with cultural narratives around GLP-1 drugs. Ozempic has been framed as a way to finally make weight loss “easier,” with an implied promise of more active, socially engaged lives. Yet some users describe feeling tired, less interested in food and less motivated to exercise, even as they see rapid changes on the scale. The new study gives those anecdotes a measurable footing and signals that clinicians may need to screen for fatigue and low activity as part of routine follow-up.
Social pressure, stigma and how people behave on weight loss drugs
The behavioral story does not stop at biology. Social attitudes around Ozempic are already shaping how people use the drug and how they feel about their weight loss. Research on public perceptions has found that many people judge GLP-1 users as less disciplined or morally weaker than those who lose weight through diet and exercise alone. One analysis of survey data, reported by ZME Science, showed that respondents were more likely to see medication-assisted weight loss as “cheating” and to blame individuals for turning to drugs.
That stigma can cut in several directions. Some patients may feel pressure to prove that they are not relying solely on injections, which might encourage intense early exercise that becomes hard to sustain. Others may internalize the message that their success “does not count,” which can sap motivation to build new habits around movement. For people who already carried shame about their bodies, the sense that their progress is being judged can make public exercise, such as going to a gym or a pool, feel even more fraught.
At the same time, the convenience of a weekly shot can reinforce a passive mindset. If the primary intervention is pharmaceutical and the scale is moving, it is easy to see walking, strength work and structured exercise as optional extras instead of core parts of treatment. The new activity data suggest that without explicit coaching and support, many patients will slide into that pattern.
Psychologically, weight loss itself can change routines in ways that unintentionally reduce movement. People who used to walk to avoid crowded buses may feel more comfortable sitting, or those who once avoided restaurants may socialize more in sedentary settings. None of those shifts are inherently negative, but they can add up to fewer daily steps if they are not balanced with intentional activity.
Long-term risks, weight regain and how care might need to change
The question looming over every GLP-1 prescription is what happens when the injections stop. Evidence from people who discontinued semaglutide and similar drugs shows that weight regain is common and often substantial. Reporting on GLP-1 discontinuation found that many patients regained a large share of the weight they had lost, sometimes within a year, once they no longer received the medication. Coverage from CBC News described patients who saw their hunger surge and their previous eating patterns return after stopping treatment.
If people are also moving less while on the drug, they may enter that off-ramp period with less muscle, lower fitness and a metabolism that has adapted to a smaller body. That combination can make weight regain faster and harder to control. It also increases the risk that future attempts at weight loss, with or without medication, will feel even more difficult.
Clinicians are already wrestling with patients who do not lose as much weight as expected on Ozempic or who plateau early. Some guidance for those scenarios encourages doctors to review adherence, check for interacting medications and emphasize lifestyle changes such as diet quality and exercise. Consumer-focused advice from WebMD similarly stresses that GLP-1 drugs work best when paired with consistent movement and eating patterns that patients can maintain.
The new study on declining activity suggests that care teams may need to be more proactive. Rather than assuming that lighter bodies will naturally become more active, clinicians might build exercise prescriptions into the treatment plan from the start. That could include referrals to physical therapists, supervised strength programs or app-based coaching that tracks both steps and resistance training, not just weight.
Policy makers and insurers will also have decisions to make. If GLP-1 drugs are reimbursed as long-term or even lifelong therapies, health systems will need to weigh their high costs against not only weight loss but also changes in functional capacity and quality of life. Objective activity data could become one metric for evaluating whether patients are gaining the broader health benefits that justify extended coverage.
